{"id":413,"date":"2015-03-10T13:13:14","date_gmt":"2015-03-10T13:13:14","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=413"},"modified":"2025-11-19T12:37:32","modified_gmt":"2025-11-19T07:07:32","slug":"413-2","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/413-2","title":{"rendered":"Antibody-Drug Conjugates Market Outlook, 2015 Report"},"content":{"rendered":"

\"dasds\"<\/p>\n

264<\/strong> Antibody-Drug Conjugates in Pipeline!!!!<\/strong><\/span><\/p>\n

Antibody-Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. Billions of dollars are spent on the chemotherapy treatments annually. The ongoing research on this therapy will replace the chemotherapeutics treatments in the near future thereby reducing its toxic side effects. Different Biotechnology companies and Pharma Companies are collaborating in all area of ADCs like linker technology, antibody production and conjugation process. There are total 264 ADCs in pipeline and two are marketed.<\/p>\n

Around 253 ADCs in Oncology<\/strong>\"dsad\"<\/p>\n

Antibody-Drug Conjugates are getting researched mostly for cancers. Cancer being the highest research area, there are 253 ADCs currently in pipeline. There are other companies which is also researching the ADC for different therapeutic areas like dermatology, immunology, women\u2019s health, gastrointestinal and ophthalmology.<\/p>\n

Four Potential ADCs in Phase III Pipeline <\/strong><\/p>\n

Companies are trying its already marketed ADC for different combinations and fo\"fff\"r different indications like Roche, Seattle Genetics conducting total 9 trials on their ADCs trastzumab emantisine and Brentuximab Vedotin. There are two new ADCs AstraZeneca\u2019s Moxetumomab Pasudotox and Pfizer\u2019s Inotuzumab Ozogamicin for Relapsed\/ Refractory Hairy Cell Leukemia and Acute Lymphoblastic Leukemia respectively.<\/p>\n

DelveInsight\u2019s Antibody-Drug Conjugate: Global Market and Pipeline Outlook, 2015<\/strong>, report provides the information across the ADCs drug value chain. The Report provides the marketed and pipeline scenario of the ADCs. The Report has covered the 264 Antibody-drug conjugates profile which gives core information of the targets, mechanism of action, development partner, Technology partner, monoclonal antibody used, linker used and cytotoxic drug with the descriptive information of the technologies. The Report also provides the assessment of the company\u2019s undergone collaborations for technology and monoclonal antibody and also gives insights over the pre-clinical and clinical data. The Report has also assessed the ADCs on geographical distribution based on the country and region.<\/p>\n

Pre-Launch Offer!!<\/strong><\/p>\n

\"dsasdas\"<\/p>\n

We are giving a limited period offer of USD 500 off on Antibody-Drug Conjugate Global Market and Pipeline Outlook, 2015.<\/p>\n

Pricing<\/strong><\/p>\n\n\n\n\n
Single-User License<\/strong><\/td>\nSite License<\/strong><\/td>\nGlobal License<\/strong><\/td>\n<\/tr>\n
USD 3500<\/td>\nUSD 7000<\/td>\nUSD 10500<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Ask for Sample Pages now!!!<\/p>\n

For Sample Pages, please write to us at info@delveinsight.com<\/p>\n

For more information about the company visit DelveInsight website<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

264 Antibody-Drug Conjugates in Pipeline!!!! Antibody-Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. Billions of dollars are spent on the chemotherapy treatments annually. The ongoing research on this therapy will replace the chemotherapeutics treatments in the near future thereby reducing its toxic side effects. Different […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[78,96,137,427,524,534],"industry":[17225],"therapeutic_areas":[17235,17228],"class_list":["post-413","post","type-post","status-publish","format-standard","hentry","category-articles","tag-antibody-drug-conjugates","tag-astrazeneca","tag-cancer","tag-oncology","tag-roche","tag-seattle-genetics","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nAntibody-Drug Conjugates Market Outlook | DelveInsight<\/title>\n<meta name=\"description\" content=\"Antibody-Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/413-2\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antibody-Drug Conjugates Market Outlook | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"Antibody-Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/413-2\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-03-10T13:13:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-19T07:07:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/03\/20041713\/dasds.png\" \/>\n\t<meta property=\"og:image:width\" content=\"571\" \/>\n\t<meta property=\"og:image:height\" content=\"351\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Antibody-Drug Conjugates Market Outlook | DelveInsight","description":"Antibody-Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/413-2","og_locale":"en_US","og_type":"article","og_title":"Antibody-Drug Conjugates Market Outlook | DelveInsight","og_description":"Antibody-Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds.","og_url":"https:\/\/www.delveinsight.com\/blog\/413-2","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2015-03-10T13:13:14+00:00","article_modified_time":"2025-11-19T07:07:32+00:00","og_image":[{"width":571,"height":351,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/03\/20041713\/dasds.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/413-2","url":"https:\/\/www.delveinsight.com\/blog\/413-2","name":"Antibody-Drug Conjugates Market Outlook | DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/413-2#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/413-2#primaryimage"},"thumbnailUrl":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/03\/dasds.png","datePublished":"2015-03-10T13:13:14+00:00","dateModified":"2025-11-19T07:07:32+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Antibody-Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/413-2"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/413-2#primaryimage","url":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/03\/dasds.png","contentUrl":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/03\/dasds.png"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Antibody-Drug Conjugates<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Oncology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Seattle Genetics<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Antibody-Drug Conjugates<\/span>","<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Oncology<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">Seattle Genetics<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 years ago","modified":"Updated 6 months ago"},"absolute_dates":{"created":"Posted on Mar 10, 2015","modified":"Updated on Nov 19, 2025"},"absolute_dates_time":{"created":"Posted on Mar 10, 2015 1:13 pm","modified":"Updated on Nov 19, 2025 12:37 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/413","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=413"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/413\/revisions"}],"predecessor-version":[{"id":31684,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/413\/revisions\/31684"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=413"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=413"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=413"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=413"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=413"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}